Pharma Pulse: The FDA Shake-Up and Growing Frustration with Prior Auth Reform

Key Takeaways

• FDA Commissioner Marty Makary resigns; Kyle Diamantas becomes acting commissioner
• Eli Lilly shows lower‑dose Zepbound maintains weight loss after switch
• FDA proposes removing GLP‑1 drugs from 503B bulk list, limiting compounding
• Only one‑third of physicians believe insurer prior‑auth reforms will improve care

Pulse Analysis

The resignation of FDA Commissioner Marty Makary comes at a pivotal moment for the agency, which has been navigating a wave of high‑visibility drug decisions. Makary’s departure, after less than a year in the role, leaves acting commissioner Kyle Diamantas to steer the FDA through ongoing debates over drug safety, labeling, and market access. Industry observers note that leadership turnover can slow policy momentum, especially as the agency prepares to finalize guidance on emerging therapies such as GLP‑1 agonists. The uncertainty may prompt companies to reassess regulatory timelines and engagement strategies.

Eli Lilly’s latest obesity data underscores a strategic shift toward dose flexibility and oral delivery in the crowded GLP‑1 market. The study showed that patients who moved from higher‑dose injectable semaglutide or tirzepatide to a lower‑dose Zepbound regimen, or switched to the oral agent Foundayo, maintained their weight‑loss gains over the long term. By demonstrating comparable efficacy with reduced dosing intensity, Lilly aims to improve adherence, lower treatment costs, and differentiate its portfolio from rivals such as Novo Nordisk. The findings could accelerate payer acceptance of mixed‑modality obesity regimens.

The broader conversation on prior‑authorization reform remains contentious, as highlighted by the American Medical Association’s survey showing only one‑third of physicians trust insurer pledges to deliver real change. Clinicians cite persistent delays in approval timelines and limited impact on patient access, especially for high‑cost therapies like GLP‑1 agents. Coupled with the FDA’s proposal to bar GLP‑1 drugs from the 503B bulk‑substance list, the regulatory and payer environments may tighten, prompting manufacturers to emphasize direct‑to‑patient programs and value‑based contracts. Stakeholders will watch for legislative action that could balance administrative burden with timely care.